An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis.

Link to article at PubMed

Related Articles

An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis.

Int J Antimicrob Agents. 2015 Oct 22;

Authors: Sunzel M, Learoyd M, Li J, Li Y, Ngo N, Edeki T

Abstract
For patients with normal renal function, the recommended ceftaroline fosamil dose is a 600mg 1-h intravenous (i.v.) infusion every 12h (q12h). In patients with a creatinine clearance of ≤30mL/min, including those with end-stage renal disease (ESRD), the recommended dose is a 200mg 1-h i.v. infusion q12h. This phase 1 study (NCT01664065) evaluated the pharmacokinetics, safety and tolerability of ceftaroline fosamil 200mg 1-h i.v. infusion in patients with ESRD. Patients with ESRD (n=8) participated in two treatment periods (ceftaroline fosamil 200mg administered pre- and post-haemodialysis) separated by >1 week. Healthy volunteers (n=7) received a single 600mg dose of ceftaroline fosamil. Blood (pre- and post-haemodialysis) and dialysate samples were obtained for pharmacokinetic analysis. In patients with ESRD, the geometric mean [coefficient of variation (%CV)] plasma ceftaroline area under the plasma concentration-time curve from zero to infinity (AUC0-∞) following post-haemodialysis ceftaroline fosamil 200mg infusion was 64.8 (38.9)μg·h/mL, similar to that in volunteers following a 600mg infusion [62.7 (9.4)μg·h/mL]. Ceftaroline AUC0-∞ decreased by ca. 50% when infusion was initiated pre-haemodialysis. In the pre-haemodialysis treatment period, 80% of the ceftaroline fosamil dose was recovered in dialysate as ceftaroline (73%) and ceftaroline M-1 (7%). The frequency of adverse events was similar across patients with ESRD (pre- and post-haemodialysis) and volunteers (43%, 50% and 43% of subjects, respectively). Ceftaroline fosamil 200mg 1-h i.v. infusion q12h, administered post-haemodialysis on dialysis days, is an appropriate dosage regimen for ESRD patients.

PMID: 26545441 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published. Required fields are marked *